Evidence snapshot
A mitochondria-targeting tetrapeptide associated with cardiolipin in the inner mitochondrial membrane. Its therapeutic development focuses on specific disease biology rather than a general stimulant effect.
Why it stands out
The appeal is addressing the structures that help cells produce usable energy. The Barth syndrome program provides a concrete example of that idea reaching patients, while broader fatigue and aging claims remain separate research questions.
How it may work
Elamipretide associates with cardiolipin in mitochondrial membranes and is designed to support mitochondrial structure and function.
What studies found
Human evidence remains disease-specific: the Barth syndrome program included a small randomized crossover trial followed by longer open-label treatment. The initial controlled phase did not meet its primary endpoints; later muscle-strength findings supported FDA accelerated approval of Forzinity in 2025. Separately, an October 2026 study reported fertility and oocyte findings mainly in aged mice, plus laboratory maturation, fertilization and cleavage measurements in aged human oocytes and oxidative-damage experiments in pig oocytes. It was not a human fertility treatment trial and did not measure pregnancy or live birth in people.
What the evidence means
Accelerated approval recognizes a promising disease-specific result and requires confirmation of patient benefit. The new fertility work is animal and laboratory evidence, not proof of a human fertility benefit. Neither line of evidence establishes treatment of ordinary fatigue, healthy aging or ME/CFS, nor makes a separately marketed SS-31 vial equivalent to Forzinity.
Safety and limitations
Injection-site reactions are common with the approved product, and serious hypersensitivity reactions have been reported. Safety information from its clinical program needs the same product and patient context as the benefit claims.
Current status
Forzinity is FDA-approved for a specific Barth syndrome indication. A research vial labeled SS-31 is not Forzinity and does not inherit that approval.
Common questions
Does FDA approval mean SS-31 is approved for everyone with low energy? No. Forzinity's indication concerns Barth syndrome in qualifying patients weighing at least 30 kg. The diagnosis and the specific medicine are central to that approval.
Personal accounts, not clinical results
A linked ME/CFS user describes more energy and capacity for mental tasks. Replies include people who did not have the same experience. These accounts are not evidence of an approved ME/CFS treatment and cannot establish who would respond.